RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Corvus Pharmaceuticals Stock

Corvus Pharmaceuticals Equity 2024

Corvus Pharmaceuticals Equity

38.68 M USD

Ticker

CRVS

ISIN

US2210151005

WKN

A2AFXS

In 2024, Corvus Pharmaceuticals's equity was 38.68 M USD, a -31.04% increase from the 56.1 M USD equity in the previous year.

Corvus Pharmaceuticals Aktienanalyse

What does Corvus Pharmaceuticals do?

Corvus Pharmaceuticals Inc. is a US biotechnology company specializing in the development of cancer treatments. It was founded in 2014 and is based in Burlingame, California. The company has a history of successfully developing medications for autoimmune diseases. Corvus Pharmaceuticals operates with a collaborative business model, working closely with leading scientists and research institutions, including Stanford University, to integrate new findings in cancer research into the development of new medications. The company is divided into different divisions to ensure efficient collaboration and expedite the launch of new medications. Two important products of Corvus Pharmaceuticals are CPI-444, an immunotherapy targeting the Adenosine A2A receptor, and CX-072, an immunotherapy targeting the CXCR4 receptor. Both medications are currently undergoing clinical trials for various types of cancer. Corvus Pharmaceuticals also collaborates with other leading companies in the field of cancer research, such as Genentech, to develop innovative therapies. In summary, Corvus Pharmaceuticals is an innovative biotechnology company specializing in the development of cancer treatments, with an effective business model and collaborations with leading scientists and research institutions. Corvus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Corvus Pharmaceuticals's Equity

Corvus Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Corvus Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Corvus Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Corvus Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Corvus Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Corvus Pharmaceuticals stock

What is the equity of Corvus Pharmaceuticals this year?

Corvus Pharmaceuticals has equity of 38.68 M USD this year.

What was the equity of Corvus Pharmaceuticals compared to the previous year?

The equity of Corvus Pharmaceuticals has increased/decreased by -31.04% decreased compared to the previous year.

What impact does a high equity have on investors of Corvus Pharmaceuticals?

A high equity is advantageous for investors of Corvus Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Corvus Pharmaceuticals?

A low equity can be a risk for investors of Corvus Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Corvus Pharmaceuticals affect the company?

An increase in equity of Corvus Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Corvus Pharmaceuticals affect the company?

A reduction in equity of Corvus Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Corvus Pharmaceuticals?

Some factors that can affect the equity of Corvus Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Corvus Pharmaceuticals so important for investors?

The equity of Corvus Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Corvus Pharmaceuticals take to change the equity?

To change equity, Corvus Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Corvus Pharmaceuticals pay?

Over the past 12 months, Corvus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Corvus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Corvus Pharmaceuticals?

The current dividend yield of Corvus Pharmaceuticals is .

When does Corvus Pharmaceuticals pay dividends?

Corvus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Corvus Pharmaceuticals?

Corvus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Corvus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Corvus Pharmaceuticals located?

Corvus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Corvus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Corvus Pharmaceuticals from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Corvus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Corvus Pharmaceuticals in the year 2023?

In the year 2023, Corvus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Corvus Pharmaceuticals pay out the dividend?

The dividends of Corvus Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Corvus Pharmaceuticals

Our stock analysis for Corvus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Corvus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.